Vireo Growth (VREOF) Total Debt (2020 - 2026)
Vireo Growth (VREOF) reported Total Debt of $198.6 million for Q1 2026, up 217.23% on a YoY basis from $62.6 million in Q1 2025, and up 38.01% sequentially from $143.9 million in Q4 2025.
Vireo Growth (VREOF) Total Debt (2020 - 2026) Analysis & Trends
Vireo Growth (VREOF) has 7 years of Total Debt data on file, last reported at $198.6 million in Q1 2026.
- For the quarter ending Q1 2026, Total Debt rose 217.23% year-over-year to $198.6 million; the trailing twelve-month figure through Mar 2026 stood at $198.6 million (up 217.23% YoY), and the FY2025 full-year result was $143.9 million, up 127.69% from the prior year.
- Total Debt rose to $198.6 million in Q1 2026, from $143.9 million in the prior quarter.
- In the past five years, Total Debt ranged from a high of $198.6 million in Q1 2026 to a low of $31.2 million in Q1 2022.
- A 5-year average of $81.9 million and a median of $60.9 million in 2024 frame the typical range for Total Debt.
- Across the five-year window, Total Debt slumped 47.53% in 2024 and surged 217.23% in 2026, its largest moves.
- Tracing VREOF's Total Debt over 5 years: stood at $58.0 million in 2022, then surged by 107.55% to $120.4 million in 2023, then plunged by 47.53% to $63.2 million in 2024, then surged by 127.69% to $143.9 million in 2025, then jumped by 38.01% to $198.6 million in 2026.
- Business Quant data shows VREOF's Total Debt at $198.6 million in Q1 2026, $143.9 million in Q4 2025, and $147.3 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 11.45 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.63 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 9.05 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 28.76 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 7.15 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 14.34 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 3.81 Bn |
| 10 | Vireo Growth | 10.57 Bn | 10.41 Bn | 59.30 Mn | 198.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 198.60 Mn |
| Dec 31, 2025 | 143.90 Mn |
| Sep 30, 2025 | 147.30 Mn |
| Jun 30, 2025 | 108.70 Mn |
| Mar 31, 2025 | 62.60 Mn |
| Dec 31, 2024 | 63.20 Mn |
| Sep 30, 2024 | 57.98 Mn |
| Jun 30, 2024 | 62.62 Mn |
| Mar 31, 2024 | 60.90 Mn |
| Dec 31, 2023 | 120.44 Mn |
| Sep 30, 2023 | 59.49 Mn |
| Jun 30, 2023 | 57.77 Mn |
| Mar 31, 2023 | 58.21 Mn |
| Dec 31, 2022 | 58.03 Mn |
| Sep 30, 2022 | 55.63 Mn |
| Jun 30, 2022 | 45.85 Mn |
| Mar 31, 2022 | 31.21 Mn |
| Dec 31, 2021 | 27.33 Mn |
| Sep 30, 2021 | 21.63 Mn |
| Jun 30, 2021 | 19.64 Mn |